Wanelad read their last ASX release...Paptype 900 patient trial...

Wanelad read their last ASX release...Paptype 900 patient trial pivotal data release is due out and if you want to see a comprehensive valuation ($2.00+) read the succinct analysis posted last night.

Doesn't have the same risk profile as drug development and has laready been used by Gribbles in nearly 10k patients!

Anyway best not to talk about GBI on the PRR thread.

***************************************

Hyosuk87

I've followed PRR and many other biotechs for quite some years...I have never held PRR up until about 4 weeks ago when I went long 8k shares...all for a bit of sport really...I get a bit bored during the colder months and this is a bit of fun...quite pathetic isn't it?

I will add that after reading the Notice of Meeting and the EXTROADINARY resolution that the directors gift themselves that quantum of shares with no effective hurdle and vesting by Sept 2009 I thought something was very very wrong and has made my sport all the more enjoyable.

cheers